Page last updated: 2024-12-07

17-alpha-hydroxypregnenolone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

17α-hydroxypregnenolone (17α-OHPREG) is a naturally occurring steroid hormone precursor. It is a key intermediate in the biosynthesis of both progesterone and dehydroepiandrosterone (DHEA). 17α-OHPREG is synthesized in the adrenal glands, ovaries, and testes. It is a potent neurosteroid with a range of biological activities, including neuroprotective, anti-inflammatory, and anxiolytic effects. Research on 17α-OHPREG focuses on its potential therapeutic applications in conditions such as Alzheimer's disease, depression, and anxiety. Its role in neurogenesis and its potential as a neuroprotective agent in aging and neurodegenerative diseases are also under investigation. 17α-OHPREG is being studied for its ability to enhance cognitive function and memory, and its potential to modulate stress responses. Its effects on hormone levels, particularly DHEA and testosterone, are also being investigated.'

17-alpha-Hydroxypregnenolone: A 21-carbon steroid that is converted from PREGNENOLONE by STEROID 17-ALPHA-HYDROXYLASE. It is an intermediate in the delta-5 pathway of biosynthesis of GONADAL STEROID HORMONES and the adrenal CORTICOSTEROIDS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

17alpha-hydroxypregnenolone : A hydroxypregnenolone carrying an alpha-hydroxy group at position 17. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID91451
CHEMBL ID408706
CHEBI ID28750
SCHEMBL ID735471
MeSH IDM0010775

Synonyms (66)

Synonym
17alpha-pregnenolone
BIDD:PXR0049
3beta,17alpha-dihydroxypregn-5-en-20-one
LMST02030089
CHEBI:28750 ,
3beta,17-dihydroxypregn-5-en-20-one
(3beta)-3,17-dihydroxypregn-5-en-20-one
5-pregnen-3.beta.,17.alpha.-diol-20-one
17-hydroxypregnenolone
17-hydroxy-.delta.5-pregnenolone
nsc 63853
17-alpha-hydroxypregnenolone
einecs 206-862-6
pregn-5-en-20-one, 3,17-dihydroxy-, (3beta)-
3beta,17alpha-dihydroxy-5-pregnen-20-one
pregn-5-en-20-one, 3-beta,17-dihydroxy-
17-hydroxy-delta5-pregnenolone
3-beta,17-alpha-dihydroxypregn-5-en-20-one
3-beta,17-dihydroxypregn-5-en-20-one
(3-beta)-3,17-dihydroxypregn-5-en-20-one
17oh-pregnenolone
5-pregnen-3beta,17alpha-diol-20-one
17oh-pregn
cmc_13421
pregn-5-en-20-one, 3beta,17-dihydroxy-
pregn-5-en-20-one, 3,17-dihydroxy-, (3-beta)-
17alpha-hydroxypregnenolone
MLS000069534
smr000058627
17alpha hydroxypregnenolone
pregnenolone, 17alpha-hydroxy-
BCE1E1D2-B635-478A-8735-7A07B4F78342
CHEMBL408706 ,
HMS2233L16
unii-77me40334s
77me40334s ,
17-oh-pregnenolone
1-[(1s,2r,5s,10r,11s,14r,15s)-5,14-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-en-14-yl]ethan-1-one
gtpl5103
bdbm50423508
SCHEMBL735471
3b,17-dihydroxy-5-pregnen-20-one
(3alpha,8alpha)-3,17-dihydroxypregn-5-en-20-one
lzz ,
3.beta.,17.alpha.-dihydroxypregn-5-en-20-one
3-.beta.,17-dihydroxypregn-5-en-20-one
pregn-5-en-20-one, 3.beta.,17-dihydroxy-
3,17-dihydroxypregn-5-en-20-one, (3.beta.,17.alpha.)-
pregn-5-en-20-one, 3,17-dihydroxy-, (3.beta.)-
3.beta.,17-dihydroxy-5-pregnen-20-one
85179-30-2
17-hydroxy-d5-pregnenolone
3b,17-dihydroxy-pregn-5-en-20-one
5-pregnen-3b,17a-diol-20-one
17a-hydroxypregnolone
3b,17a-dihydroxypregn-5-en-20-one
17a-hydroxypregnenolone
pregn-5-en-20-one, 3,17-dihydroxy-, (3b)-
DTXSID20894988
Q35666789
1-((3s,8r,10r,13s,17r)-3,17-dihydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)-ethanone
1-((3s,8r,9s,10r,13s,14s,17r)-3,17-dihydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)ethanone
HY-113263
CS-0059458
MS-25014
PD047827

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" To investigate the mechanism of the fall, metabolism of [3H] progesterone in vitro by ovin placental tissue was studied in five ewes before and after intra-foetal administration of dexamethasone in a dosage sufficient to induce parturition, and in one ewe after the spontaneous onset of labour at 143 days of gestation."( Mechanism of action of glucocorticoids in induction of ovine parturition: effect on placental steroid metabolism.
Anderson, AB; Flint, AP; Turnbull, AC, 1975
)
0.25
" To distinguish between these possibilities, we have analyzed the ovarian steroid responses to nafarelin for the apparent efficiency of the steroidogenic steps and the apparent dose-response relationships between blood LH and steroid levels."( Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.
Barnes, RB; Ehrmann, DA; Rosenfield, RL, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
hydroxypregnenoloneA C21-steroid that is pregnenolone in which a hydrogen attached to a carbon is substituted by a hydroxy group.
17alpha-hydroxy steroidThe alpha-stereoisomer of 17-hydroxy steroid.
3beta-hydroxy-Delta(5)-steroidAny 3beta-hydroxy-steroid that contains a double bond between positions 5 and 6.
17alpha-hydroxy-C21-steroidAny C21-steroid carrying a hydroxy substituent at the 17alpha-position. Note that individual examples may have ring substituents at other positions and/or contain double bonds, aromatic A-rings, expanded/contracted rings etc., so the formula and mass may vary from that given for the generic structure.
tertiary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (29)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Metabolism of steroids111135
Metabolism of steroid hormones2537
Glucocorticoid biosynthesis616
Androgen biosynthesis916
Androgen and Estrogen Metabolism1230
Steroidogenesis1142
17-beta Hydroxysteroid Dehydrogenase III Deficiency1230
Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency1142
Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH1142
Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency1142
Aromatase Deficiency1230
17-alpha-Hydroxylase Deficiency (CYP17)1142
11-beta-Hydroxylase Deficiency (CYP11B1)1142
21-Hydroxylase Deficiency (CYP21)1142
Corticosterone Methyl Oxidase I Deficiency (CMO I)1142
Corticosterone Methyl Oxidase II Deficiency (CMO II)1142
Apparent Mineralocorticoid Excess Syndrome1142
3-beta-Hydroxysteroid Dehydrogenase Deficiency1142
Steroid hormone precursor biosynthesis015
Androgen receptor network in prostate cancer434
Male steroid hormones in cardiomyocyte energy metabolism1119
androgen biosynthesis715
Biosynthesis of aldosterone and cortisol010
Glucocorticoid & Mineralcorticoid Metabolism013
Glucocorticoid and Mineralcorticoid Metabolism04
Biochemical pathways: part I0466
Classical pathway of steroidogenesis with glucocorticoid and mineralocorticoid metabolism325
Steroid biosynthesis04

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, CruzipainTrypanosoma cruziPotency25.11890.002014.677939.8107AID1476
IDH1Homo sapiens (human)Potency0.46110.005210.865235.4813AID686970
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency0.56230.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sex hormone-binding globulinHomo sapiens (human)Kd0.43650.00020.34964.7863AID318680
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
androgen bindingSex hormone-binding globulinHomo sapiens (human)
protein bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingSex hormone-binding globulinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular regionSex hormone-binding globulinHomo sapiens (human)
extracellular exosomeSex hormone-binding globulinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID624617Specific activity of expressed human recombinant UGT2B172000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID51049Binding affinity against corticosteroid-binding globulin1993Journal of medicinal chemistry, Feb-19, Volume: 36, Issue:4
Structure-activity relationships from molecular similarity matrices.
AID212931Binding affinity towards human testosterone binding globulin.1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.
AID468984Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 0.3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID212920Binding affinity against transport protein testosterone binding globulin.1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark.
AID212737Binding affinity against testosterone-binding globulin (TeBG)1993Journal of medicinal chemistry, Feb-19, Volume: 36, Issue:4
Structure-activity relationships from molecular similarity matrices.
AID51054Binding affinity for corticosteroid binding globulin is expressed as log(1/k)1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID51062In silico steroid binding affinity to transport protein corticosteroid binding globulin1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark.
AID228061Binding affinity towards human testosterone binding globulin.1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods.
AID318680Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
AID51052In silico binding affinity to corticosteroid binding globulin (CBG)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 1. Method and validations.
AID220020Binding affinity towards human corticosteroid binding globulin.1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods.
AID468985Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID51048In silico binding affinity to human corticosteriod binding globulin1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.
AID212919Binding affinity towards testosterone binding globulin is expressed as log(1/k).1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (616)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990408 (66.23)18.7374
1990's77 (12.50)18.2507
2000's60 (9.74)29.6817
2010's61 (9.90)24.3611
2020's10 (1.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.44 (24.57)
Research Supply Index6.46 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (0.79%)5.53%
Reviews17 (2.68%)6.00%
Case Studies20 (3.15%)4.05%
Observational1 (0.16%)0.25%
Other592 (93.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]